ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System
Retrieved on:
Tuesday, August 10, 2021
BLA, United States, Collection, Safety, San Jose BioCenter, Patient, Health, Private Securities Litigation Reform Act, Risk, U.S. Securities and Exchange Commission, Review, Biologics license application, 8-K, Technology, Blood, Immunity, Solution, NYSE, Immunodeficiency, Forward-looking statement, ADMA, Food and Drug Administration, SE, Plasma, Environment, Infection, NASDAQ, FDA, GLOBE, Marketing, Hepatitis B virus, HAE, Medical device, Risk management
In conjunction with the plasma collection center opening, ADMA also announced the implementation of the Haemonetics Persona Plasma Collection Solution for the NexSys PCS system (Persona) across its plasma collection center network.
Key Points:
- In conjunction with the plasma collection center opening, ADMA also announced the implementation of the Haemonetics Persona Plasma Collection Solution for the NexSys PCS system (Persona) across its plasma collection center network.
- We are pleased that ADMA has chosen to adopt the Haemonetics Persona Plasma Collection Solution for the NexSys PCS system.
- The implementation of Persona technology and the opening of ADMAs newest plasma collection center directly advances the Companys near term and ongoing strategic objectives, said Adam Grossman, President and Chief Executive Officer of ADMA.
- With todays plasma collection center opening, ADMA now has eight collection facilities under its corporate umbrella at various stages and remains on track to have 10 or more centers in operation by 2024.